About wuxi biologics (cayman) inc. - WXIBF
Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. It operates through the Biologics and XDC segments. The company was founded on February 27, 2014, and is headquartered in Wuxi, China.
WXIBF At a Glance
Wuxi Biologics (Cayman), Inc.
108, Meiliang Road
Wuxi, Jiangsu 214092
| Phone | N/A | Revenue | 2.40B | |
| Industry | Biotechnology | Net Income | 479.85M | |
| Sector | Health Technology | 2023 Sales Growth | 6.032% | |
| Fiscal Year-end | 12 / 2024 | Employees | 12,740 | |
| View SEC Filings |
WXIBF Valuation
| P/E Current | 26.716 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 32.877 |
| Price to Sales Ratio | 6.857 |
| Price to Book Ratio | 2.838 |
| Price to Cash Flow Ratio | 25.021 |
| Enterprise Value to EBITDA | 21.395 |
| Enterprise Value to Sales | 6.68 |
| Total Debt to Enterprise Value | 0.04 |
WXIBF Efficiency
| Revenue/Employee | 188,717.471 |
| Income Per Employee | 37,664.592 |
| Receivables Turnover | 2.54 |
| Total Asset Turnover | 0.318 |
WXIBF Liquidity
| Current Ratio | 2.616 |
| Quick Ratio | 2.375 |
| Cash Ratio | 1.475 |
WXIBF Profitability
| Gross Margin | 40.083 |
| Operating Margin | 23.087 |
| Pretax Margin | 24.502 |
| Net Margin | 19.958 |
| Return on Assets | 6.353 |
| Return on Equity | 8.945 |
| Return on Total Capital | 7.581 |
| Return on Invested Capital | 8.208 |
WXIBF Capital Structure
| Total Debt to Total Equity | 11.31 |
| Total Debt to Total Capital | 10.161 |
| Total Debt to Total Assets | 8.062 |
| Long-Term Debt to Equity | 9.496 |
| Long-Term Debt to Total Capital | 8.532 |